Target Information

Target General Infomation
Target ID
T26220
Target Name
Somatostatin receptor
Target Type
Clinical Trial
Disease Alzheimer disease [ICD9: 331; ICD10: G30]
Acromegaly [ICD9: 253; ICD10: E22.0]
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3]
Duodenal ulcers [ICD10: K25-K27]
HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10: B17.1, B18.2]
Melanoma [ICD9: 172; ICD10: C43]
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89]
BioChemical Class
G protein-coupled receptors (GPCR)
Drugs and Mode of Action
Drug(s) 177Lu-DOTA-octreotate (neuroendocrine tumors), Advanced Accelerator Applications Drug Info Phase 3 Melanoma [523870]
177Lu-DOTATATE Drug Info Phase 2 HCV infection [524302]
Edotreotide Drug Info Phase 2 Acromegaly [521481], [540994]
FK-962 Drug Info Phase 2 Alzheimer disease [521603]
Somatoprim Drug Info Phase 2 Acromegaly [543166], [547415]
BIM-23268 Drug Info Discontinued in Phase 2 Acromegaly [539319], [547475]
FK-960 Drug Info Discontinued in Phase 2 Cognitive disorders [546546]
SEGLITIDE Drug Info Discontinued in Phase 2 Pain [539307], [544698]
Modulator 177Lu-DOTA-octreotate (neuroendocrine tumors), Advanced Accelerator Applications Drug Info [532708]
177Lu-DOTATATE Drug Info [532708]
BIM-23268 Drug Info [1572591]
Edotreotide Drug Info [1572591]
FK-960 Drug Info
FK-962 Drug Info
Ilatreotide Drug Info
SEGLITIDE Drug Info [544040]
Somatoprim Drug Info
References
Ref 521481ClinicalTrials.gov (NCT00006370) Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 521603ClinicalTrials.gov (NCT00087724) A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
Ref 523870ClinicalTrials.gov (NCT01578239) A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours. U.S. National Institutes of Health.
Ref 524302ClinicalTrials.gov (NCT01860742) Randomized Phase III of PRRT Versus Interferon. U.S. National Institutes of Health.
Ref 539307(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2051).
Ref 539319(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2083).
Ref 540994(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5638).
Ref 543166(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8487).
Ref 544698Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000642)
Ref 546546Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008887)
Ref 547415Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016053)
Ref 547475Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016700)
Ref
Ref 532708Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25.
Ref 544040Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria.. Br J Pharmacol. 1993 August; 109(4): 898-899.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.